Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

MERZ PHARMACEUTICALS GMBH

Home Clinical Trial Sponsors and OrganizationsMERZ PHARMACEUTICALS GMBH

MERZ PHARMACEUTICALS GMBH

ACTIVE

8427 Plymouth Ln, Frisco, Texas, United Stateswww.radiesse.deSubsidiary101–250 employeesEstablished: 1908-01-01

Part of Merz Pharma Gmbh & Co. Kgaa

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

178

106 active

Approvals

28

Total approvals

Agencies

5

Regulatory bodies

Founded

1908

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

56

31.5%

Phase 3

36

20.2%

Phase 2

12

6.7%

Phase 4

7

3.9%

Not Applicable

3

1.7%

Unknown

1

0.6%

Trial Status Distribution

Active, not recruiting

105

59.0%

Completed

63

35.4%

Not yet recruiting

1

0.6%

Recruiting

2

1.1%

Terminated

5

2.8%

Unknown

1

0.6%

Withdrawn

1

0.6%

Clinical Trials

Trials sponsored by this organization (178)

Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by stroke or traumatic brain injury.

Jul 2024445 participants

A clinical study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy.

Mar 2024130 participants

Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by stroke or traumatic brain injury.

Active, not recruiting

Jan 2023600 participants

A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

Oct 202240 participants

Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by stroke or traumatic brain injury.

Active, not recruiting

Aug 2022600 participants

Open-label, multicenter, uncontrolled, randomized, post market clinical follow-up (PMCF) study to confirm effectiveness and safety of Belotero® Revive in facial skin revitalization and photo-damaged skin treatment

Jul 2021159 participants

A Study to Investigate the Efficacy and Safety of NT201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

Active, not recruiting

Jul 202175 participants

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

Feb 202178 participants

Page 1 of 23

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

6

Approvals

EMA

European Medicines Agency

2

Approvals

CANADA

Health Canada

4

Approvals

SFDA

Saudi Food and Drug Authority

2

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

14

Approvals

Recent Approvals

XEOMIN 50 U Vial

XEOMIN 100 U Vial

Compound Heparin Sodium and Allantoin Gel

Compound Heparin Sodium and Allantoin Gel

Botulinum Toxin Type A for Injection

Botulinum Toxin Type A for Injection

Ornithine Aspartate Injection

AXURA 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

AXURA 10 mg COMPRIMIDOS RECUBIERTOS CON PELICULA

News

No news articles found

On this page

Overview
Clinical Trials178
Approvals28
News

Back to Organizations